Linked Life Data

2816616

Source:http://linkedlifedata.com/resource/pubmed/id/2816616

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1989-12-15
pubmed:abstractText
We treated 13 patients with superficial bladder cancer via intravesical bacillus Calmette-Guerin (BCG) for 1) prophylaxis of recurrent tumor (prophylaxis group, 8 patients), and 2) therapy of carcinoma in situ (CIS group, 5 patients), with a mean follow up of 13.3 and 14.2 months, respectively. BCG (Tokyo 172 strain) was given intravesically (80 mg in 40 ml, saline) weekly for 8 weeks after transurethral resection or biopsies. In the prophylaxis group, the recurrence rate per 100 patient-months was significantly decreased from 16.1 to 2.83, before and after the BCG therapy (p less than 0.005, chi-square). In 6 patients on whom previous intravesical chemotherapy (MMC and/or ADM) was unsuccessful, the recurrence rate at 100 patient-months was significantly decreased from 15.3 to 2.33, before and after the BCG therapy (p less than 0.005, chi-square). Therefore, we considered that BCG therapy was effective for the patients on whom previous intravesical chemotherapy was unsuccessful. In the CIS group, urine cytology changed to negative in all patients after the BCG therapy. Four of the 5 patients had no recurrence for a mean follow up of 13.8 months. In our cases (12 cases), OKT-4, and OKT-8 proportion of peripheral blood lymphocytes measured from immune reactions had not significantly changed after BCG therapy. This study suggests that BCG is effective not only in therapy of CIS, but in prophylaxis of previously treated cases.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0018-1994
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1503-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
[Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
pubmed:affiliation
Department of Urology, Public Toyooka Hospital.
pubmed:publicationType
Journal Article, English Abstract